Pharmaceutical Cold-Chain Incident Report Form

1. Shipment Air Waybill (AWB), Carrier & Batch Lot Metadata

This section captures fundamental shipment identification and product metadata essential for traceability and regulatory compliance. Accurate completion is critical for initiating investigation and disposition workflows.

 

Master Air Waybill (MAWB) Number

House Air Waybill (HAWB) Number

Carrier Name

Transport Mode

Flight Number

Vessel Name & Voyage Number

 

Vehicle Registration Number

 

Describe Intermodal Journey Sequence

Origin Airport/Port Code

Destination Airport/Port Code

Shipment Departure Date/Time

Shipment Arrival Date/Time

Product Batch/Lot Details

Product Name

Batch / Lot #

Quantity (Units)

Dosage Form

Strength / Potency

Manufacturer Name

A
B
C
D
E
F
1
 
 
 
 
 
 
2
 
 
 
 
 
 
3
 
 
 
 
 
 
4
 
 
 
 
 
 
5
 
 
 
 
 
 
6
 
 
 
 
 
 
7
 
 
 
 
 
 
8
 
 
 
 
 
 
9
 
 
 
 
 
 
10
 
 
 
 
 
 

Total Declared Value of Shipment

Required Storage Temperature Range

Temperature Set Point

Packaging Configuration

 

Container ID / Serial Number

Thermal Shipper Model

Number of PCM Packs Used

Dry Ice Weight (kg)

Liquid Nitrogen Fill Level (%)

Shipper/Consignor Name

Consignee Name

Associated Documentation References

2. Continuous Temperature Sensor Telematics & Thermal Exposure Duration

This section documents the digital temperature monitoring ecosystem, sensor performance, and precise thermal exposure metrics. The data captured here forms the technical foundation for deviation assessment and determines the scope of product impact evaluation.

 

Temperature Monitoring Device Serial Number

Sensor Type

Is the temperature monitoring device calibrated and within valid certification period?

 

Explain calibration status and impact on data reliability:

Was the temperature data successfully downloaded/retrieved from the device?

 

Describe data retrieval failure and alternative evidence:

Temperature Excursion Start Date/Time

Temperature Excursion End Date/Time

Total Thermal Exposure Duration (minutes)

Maximum Temperature Recorded (°C)

Minimum Temperature Recorded (°C)

Mean Kinetic Temperature (MKT) During Excursion (°C)

Which temperature threshold(s) were breached? (Select all that apply)

Did the temperature monitoring device issue real-time alerts during the excursion?

 

Describe alert recipients, response time, and immediate actions taken upon alert:

 

Explain why alerts were not generated or received:

Ambient Environmental Conditions During Incident

Upload Photograph of Temperature Logger Display/Screenshot at Time of Discovery

Choose a file or drop it here

Upload Complete Temperature Data File (PDF/CSV/XML format)

Choose a file or drop it here
 

Are there any gaps or anomalies in the temperature data record?

 

Describe data gaps, their duration, and potential causes:

3. Biological Integrity Assessment & Product Potency Risk Audit

This section evaluates the potential impact on product quality, safety, and efficacy based on stability profiles, visual inspection, and scientific risk assessment. The findings here directly influence quarantine decisions and regulatory reporting obligations.

 

Has a visual inspection of the product been completed?

 

Visual Inspection Findings (Select all observed anomalies)

 

Explain why visual inspection was not performed and schedule for completion:

Time Out of Refrigeration (TOR) - Total Accumulated Minutes

Is there available stability data covering the observed temperature excursion conditions?

 

Reference stability study protocols, batch numbers, and conclusions that support product integrity:

 

Explain the absence of stability data and the implications for risk assessment:

Product Potency Risk Assessment Matrix - Rate each factor based on observed conditions

Very Low Risk

Low Risk

Moderate Risk

High Risk

Critical Risk

Severity of temperature deviation from specification

Duration of thermal exposure

Product sensitivity to temperature (based on known stability profile)

Integrity of primary packaging post-incident

Phase of product lifecycle (clinical vs commercial)

Availability of supportive stability data

Overall Product Integrity Confidence Level (1 = No Confidence, 5 = Full Confidence)

Has the manufacturer or Marketing Authorization Holder been notified of the incident?

 

Provide notification timestamp, contact person, and preliminary guidance received:

 

Explain the delay and planned notification schedule:

Is regulatory authority notification required based on risk assessment?

 

Which regulatory agencies require notification? (Select all applicable)

Will product samples be retained for analytical testing?

 

Specify sample quantity, storage location, testing laboratory, and planned test protocols:

Preliminary Product Disposition Recommendation

Upload Supporting Documentation (Stability Reports, Manufacturer Correspondence, Photographs)

Choose a file or drop it here
 

4. Quarantine Isolation Protocol & Replacement Freight Dispatch Strategy

This section documents immediate containment measures, quarantine logistics, and remedial shipment arrangements to maintain supply chain continuity while ensuring compromised product does not reach patients.

 

Immediate Containment Actions Taken Upon Discovery (Select all applicable)

Quarantine Location (Warehouse Zone/Bay Number)

Is the quarantine area under continuous temperature monitoring?

 

Describe alternative monitoring arrangements and risk mitigation:

Is a replacement shipment required to fulfill customer orders?

 

Replacement Freight Dispatch Details

Replacement AWB Number

Replacement Carrier Name

Planned Dispatch Date/Time

Expedited Shipping Service

New Temperature Monitoring Device ID

Enhanced Monitoring Confirmed

A
B
C
D
E
F
1
 
 
 
 
 
2
 
 
 
 
 
3
 
 
 
 
 
4
 
 
 
 
 
5
 
 
 
 
 

Has the consignee/customer been notified of the incident and potential delivery delay?

 

Provide notification timestamp, method, contact person, and customer response:

Incident Cost Tracking & Financial Impact

Cost Category

Quantity / Count

Unit Cost

Total Cost

Insurance Claimable

A
B
C
D
E
1
 
 
 
$0.00
2
 
 
 
$0.00
3
 
 
 
$0.00
4
 
 
 
$0.00
5
 
 
 
$0.00
6
 
 
 
$0.00
7
 
 
 
$0.00
8
 
 
 
$0.00
9
 
 
 
$0.00
10
 
 
 
$0.00

Root Cause Analysis - Preliminary Assessment

Preventive Actions Implemented to Avoid Recurrence (Select all applicable)

Is a formal Corrective and Preventive Action (CAPA) investigation required?

 

CAPA Reference Number

5. Head of Global Logistics & Quality Control Officer Joint Clearance Sign-Off

This final section requires dual-authority approval to formally close the incident report and authorize final product disposition. Both signatories attest that all investigations, risk assessments, and regulatory obligations have been satisfactorily completed according to organizational quality standards.

 

Executive Summary of Incident, Investigation, and Final Disposition Decision

Final Product Disposition Decision

Have all regulatory notification obligations been fulfilled?

 

Describe pending notifications and completion timeline:

Has the incident been formally documented in the quality management system?

 

Explain QMS documentation status and planned completion:

Head of Global Logistics Signature

Quality Control Officer - Digital Signature

I confirm that all information provided in this incident report is accurate and complete to the best of my knowledge, and that all necessary investigations, risk assessments, and corrective actions have been conducted according to applicable quality standards and regulatory requirements.

Additional Comments or Special Instructions

Should this incident be escalated to executive management review?

 

Rationale for executive escalation:

To configure an element, select it on the form.

To add a new question or element, click the Question & Element button in the vertical toolbar on the left.